Vol.
42
No.
42
November 11, 2016Nov 11, 2016
Free
FDA Eager to Approve PD-1 and PD-L1 Drugs in Novel Combinations, New Settings
Cover Story
Conversation with The Cancer Letter
In an in-depth interview with The Cancer Letter, an FDA official clarified the agency's criteria for approval of drugs that target PD-1 and PD-L1.

Login